<DOC>
	<DOCNO>NCT02144311</DOCNO>
	<brief_summary>The purpose research study learn difference see scan surgery match difference see look tumor sample pathology genetic test . In study use Magnetic Resonance Imaging [ MRI ] Positron Emission Tomography [ PET ] scan . No direct clinical benefit come result study .</brief_summary>
	<brief_title>Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer : Linking In-vivo Imaging Phenotypes With Histology And Genomics</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>â‰¥18 year age day sign informed consent . Histologically confirm suspected stage III IV highgrade serous ovarian cancer . Scheduled undergo primary debulking surgery . Pregnant patient Patients general medical psychiatric condition , physiologic status unrelated presence ovarian cancer give valid inform consent Patients unwilling unable undergo MRI include patient contraindication MRI presence cardiac pacemaker noncompatible intracranial vascular clip , claustrophobia , inability lie flat duration study etc . Patients metallic hip implant metallic implant device pelvis might distort local magnetic field compromise quality MRI/ Radiotherapy abdomen pelvis within 6 month screen visit . Subjects current diagnosis epithelial ovarian tumor low malignant potential ( borderline carcinoma ) eligible Patients synchronous primary endometrial cancer past history endometrial cancer , unless follow condition meet : Stage great IB No superficial myometrial invasion No vascular lymphatic invasion No poorly differentiate subtypes , include serous , clear cell , FIGO Grade 3 lesion . Patients receive prior chemotherapy abdominal pelvic tumor exclude . Patients receive neoadjuvant chemotherapy prior initial debulking exclude . Patients may receive prior adjuvant chemotherapy breast cancer . With exception nonmelanoma skin cancer specific malignancy note , subject invasive malignancy ( ) evidence cancer present within last 3 year exclude . Unresolved bowel obstruction . History current evidence condition , therapy , lab abnormality might confound result study , interfere patient 's participation full duration study . Absence target lesion ( &gt; 2.0 cm ) stag CT Patients unlikely optimally debulked surgery ( tumor implant difficult reach place [ i.e . falciform ligament porta hepatis ] , suprarenal retroperitoneal lymphadenopathy )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MRI</keyword>
	<keyword>FDG PET/CT</keyword>
	<keyword>histologic heterogeneity</keyword>
	<keyword>14-061</keyword>
</DOC>